Viralytics Ltd SP Ad (VRACY) 2.2300 $VRACY Non-Small

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Viralytics Ltd SP Ad (VRACY) 2.2300 $VRACY

Non-Small Cell Lung Cancer - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnx7gl/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Non-Small Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Non-Small Cell Lung Cancer - Overview - Pipeline Products for Non-Small Cell Lung Cancer - Comparative Analysis - Non-Small Cell Lung Cancer - Therapeutics under Development by Companies - Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Non-Small Cell Lung Cancer - Products under Development by Companies - Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - Arch Biopartners, Inc. - Ariad Pharmaceuticals, Inc. - Arog Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Axelar AB - CTI BioPharma Corp. - CureFAKtor Pharmaceuticals, LLC - CureVac GmbH - CytRx Corporation - Daiichi Sankyo Company, Limited - DanDrit Biotech A/S - Viralytics Ltd. - XBiotech USA, Inc. - Zhejiang BetaPharma Co., Ltd. - Zyngenia, Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/pn...small_cell
AZN: 34.28 (-0.02), ACH: 8.89 (+0.05), CYTR: 0.61 (unch), AVEO: 0.99 (+0.03), ARQL: 1.57 (-0.07), CTIC: 0.36 (-0.01), ARRY: 4.54 (+0.06)

World Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Pipeline Review, H2 2015
M2 - Mon Dec 14, 10:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/2kz5rl/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Ambrx, Inc. - Amgen Inc. - Arrowhead Research Corporation - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - BIND Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - GenSpera, Inc. - GlaxoSmithKline Plc - GTx, Inc. - Medivation, Inc. - NewLink Genetics Corporation - Orion Oyj - Pfizer Inc. - Progenics Pharmaceuticals, Inc. - Sanofi - Sotio a.s. - Sun Pharma Advanced Research Company Ltd. - Supratek Pharma Inc. - Taiho Pharmaceutical Co., Ltd. - Takeda Pharmaceutical Company Limited - Viralytics Ltd. For more information visit http://www.researchandmarkets.com/research/2kz5rl/metastatic
ADXS: 14.26 (+1.40), EBS: 29.78 (-0.91), ARWR: 5.99 (+0.09), AMBX: (), PFE: 35.44 (+0.29), ADMP: 2.64 (-0.06), AMGN: 173.66 (+0.99), LLY: 81.56 (-0.86), BIND: 0.78 (-0.09), GSK: 44.89 (-0.19), BMY: 63.28 (-12.04), MDVN: 63.25 (-0.48), PGNX: 6.28 (+0.35), GTXI: 0.54 (-0.01), AZN: 34.28 (-0.02), NLNK: 11.00 (+0.15), ABBV: 66.54 (+0.44)

Viralytics Completes $28 million Placement -- SPP to Follow
PR Newswire - Mon Dec 14, 5:00AM CST
Viralytics Limited (Viralytics) announces that it has completed a placement of 46,118,270 shares to international and domestic sophisticated or professional investors at an issue price of $0.615 per share to raise $28,362,736. The placement was significantly oversubscribed with strong demand from international specialist healthcare investment funds, including two New York based Funds who are new to the register. The price represents a 5.2% discount to the VWAP for the 5 days up to and including 9 December 2015.

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2015 - 15 Companies & 21 Drug Profiles
M2 - Mon Dec 07, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/s7bjp9/non_muscle) has announced the addition of the "Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Altor BioScience Corporation - APIM Therapeutics AS - Astellas Pharma Inc. - Bavarian Nordic A/S - BioCancell Ltd - Celgene Corporation - Cold Genesys, Inc. - Heat Biologics, Inc. - Spectrum Pharmaceuticals, Inc. - TARIS BioMedical, Inc. - Telesta Therapeutics Inc. - Telormedix SA - Vakzine Projekt Management GmbH - Viralytics Ltd. - Viventia Biotechnologies Inc. Drug Profiles - ALT-801 - ALT-803 - apaziquone - APL-1202 - ATX-101 - BC-819 - Biologic for Superficial Bladder Cancer - CG-0070 - CV-301 - CVA-21 - DAB-389EGF - docetaxel - Drug for NMIBC - erlotinib hydrochloride - imiquimod - lenalidomide - mitomycin SR - Monoclonal Antibody to Inhibit EGFR for Superficial Bladder Cancer - oportuzumab monatox - rAd-IFN - sirolimus albumin-bound - TD-210 - Urocidin - vesigenurtucel-L - VPM-1002 For more information visit http://www.researchandmarkets.com/research/s7bjp9/non_muscle
HTBX: 1.31 (+0.20), SPPI: 7.10 (+0.07), CELGZ: 1.11 (+0.01)

Viralytics and Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. to Collaborate on Combination Clinical Trial of CAVATAK(TM) and KEYTRUDA(R) in Lung and Bladder Cancer
PR Newswire - Fri Nov 06, 5:00AM CST
Viralytics Limited (ASX: VLA, OTC: VRACY) announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK(TM), with MSD's KEYTRUDA®, an anti-PD-1 (programmed death receptor-1) therapy.
MRK: 63.86 (+6.02)

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 98.94 (-0.68), CLDX: 4.66 (+0.15), CYCC: 4.83 (-0.04), IMMU: 2.99 (+0.15), EBS: 29.78 (-0.91), INCY: 90.84 (+0.72), TGTX: 6.02 (+0.15), AMGN: 173.66 (+0.99), LLY: 81.56 (-0.86), BMY: 63.28 (-12.04), GILD: 80.41 (+0.64), CELGZ: 1.11 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 113

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 34

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 86

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 16

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 427

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 372

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 42

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 103

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 55

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading

Top 5 Most Recently Viewed Articles

Insigneo Welcomes Esteban Diaz to Enhance Wealth Management

Updated Category News Views 159

Insigneo Strengthens Its Wealth Management Team Insigneo, a prominent name in wealth management, proudly announces the addition of Esteban Diaz as Senior Vice President. This significant recruitment is part of the firm’s ongoing commitment to enhancing its network, particularly in serving high-net-worth clients in the Latin American region. About Esteban Diaz's...

Continue Reading
Exploring RBC Bearings: A Five-Year Investment Journey

Updated Category News Views 172

RBC Bearings: A Strong Investment Over Time RBC Bearings has proven to be a formidable player in the market, showcasing impressive performance over the last five years. With an average annual return of 18.74%, any investment made during this period would have reaped considerable rewards. The Growth of a $1000 Investment Imagine if you had decided to invest $1000 in RBC...

Continue Reading
ANI Pharmaceuticals Enhances Ophthalmology Strategy with Experts

Updated Category News Views 227

ANI Pharmaceuticals Launches FutureVision Advisory Council In a strategic move to bolster its ophthalmology and retina franchise, ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has established the FutureVision Advisory Council. This dedicated council aims to guide the ongoing innovations within ANI's Rare Disease portfolio, focusing particularly on ophthalmological care....

Continue Reading
Unlocking Financial Freedom: The CESUR Mining Game Changer

Updated Category News Views 99

Understanding CESUR Mining and Its Impact CESUR Mining is quickly becoming a significant player in the world of cryptocurrency. This innovative platform enables users to tap into the potential of cloud mining, allowing them to earn passive income without the need for technical knowledge or constant monitoring. Established with the vision to simplify the mining process,...

Continue Reading
Understanding Nvidia's Role in the S&P 500 Market Dynamics

Updated Category News Views 204

Nvidia's Influence on the S&P 500 Market The stock market can be quite a wild ride, with swings that can astonish even the most experienced investors. Recently, stocks started off relatively flat but soon encountered volatility, leading to a significant rally largely fueled by news surrounding Nvidia. This surge prompts important questions about how the S&P 500 will...

Continue Reading